Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Agomelatine (S20098) is a novel antidepressant drug with melatonergic agonist and 5-HT2C receptor antagonist properties, displaying antidepressant/anxiolytic-like properties in animal models and in humans. In a depression/anxiety-like mouse model in which the response of the HPA axis is blunted, we investigated whether agomelatine could reverse behavioural deficits related to depression/anxiety compared to the classical selective serotonin reuptake inhibitor, fluoxetine. Adult mice were treated for 8 wk with either vehicle or corticosterone (35 μg/ml.d) via drinking water. During the final 4 wk, animals were treated with vehicle, agomelatine (10 or 40 mg/kg i.p.) or fluoxetine (18 mg/kg i.p.) and tested in several behavioural paradigms and also evaluated for home-cage activity. Our results showed that the depressive/anxiety-like phenotype induced by corticosterone treatment is reversed by either chronic agomelatine or fluoxetine treatment. Moreover, agomelatine increased the dark/light ratio of home-cage activity in vehicle-treated mice and reversed the alterations in this ratio induced by chronic corticosterone, suggesting a normalization of disturbed circadian rhythms. Finally, we investigated the effects of this new antidepressant on neurogenesis. Agomelatine reversed the decreased cell proliferation in the whole hippocampus in corticosterone-treated mice and increased maturation of newborn neurons in both vehicle- and corticosterone-treated mice. Overall, the present study suggests that agomelatine, with its distinct mechanism of action based on the synergy between the melatonergic agonist and 5-HT2C antagonist properties, provides a distinct antidepressant/anxiolytic spectrum including circadian rhythm normalization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 6×
“For each of the five body areas, a score of 0 was given for a well-groomed coat and 1 for an unkempt coat (Santarelli et al. 2003).”
BackgroundInfluentialSelf-citationAre the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
Fanselow, M. S., & Dong, H.-W. (2010) · Neuron · doi:10.1016/j.neuron.2009.11.031 · Cited by 3,358 · cited 3×
“…interest, since the hippocampus may be functionally segregated along its dorsal/ventral axis, with the dorsal hippocampus more responsible for spatial memory and the ventral hippocampus implicated in anxiety and mood regulation (Bannerman et al. 2004; Fanselow & Dong, 2010 ; Moser & Moser, 1998).”
BackgroundResearch and treatment approaches to depression
Wong, M.-L., & Licinio, J. (2001) · Nature Reviews Neuroscience · doi:10.1038/35072566 · Cited by 656
Circadian rhythm disturbances in depression
Germain, A., & Kupfer, D. J. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.964 · Cited by 644 · cited 2×
“This component of the pharmacological activity of agomelatine is important since abnormal circadian rhythms including modifications of active/sleep state have been described in depression as a major symptom (Germain & Kupfer, 2008 ; Healy, 1987; Mendelson et al. 1987 ; Perlis et al. 1997).”
BackgroundSurget, A., Saxe, M., Leman, S., Ibarguen-Vargas, Y., Chalon, S., Griebel, G., Hen, R., & Belzung, C. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.02.022 · Cited by 556 · cited 1×
“Long-term glucocorticoid exposure, similar to chronic stress (Surget et al. 2008), induced physical changes including deterioration of the coat state.”
BackgroundSelf-citationHigh-speed imaging reveals neurophysiological links to behavior in an animal model of depression
Airan, R. D., Meltzer, L. A., Roy, M., Gong, Y., Chen, H., & Deisseroth, K. (2007) · Science · doi:10.1126/science.1144400 · Cited by 396
Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis
Banasr, M., Soumier, A., Hery, M., Mocaër, E., & Daszuta, A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.025 · Cited by 318 · cited 7×
“…other studies have shown that 3-wk treatment with agomelatine promoted cell proliferation in the ventral hippocampus of non-stressed Wistar rats (Banasr et al. 2006 ; Soumier et al. 2009), wild-type GR-i mice (Paı̈zanis et al. 2010), or the dorsal part of the hippocampus of Sprague–Dawley rats…”
BackgroundResultInfluentialLeproult, R., Van Onderbergen, A., L’Hermite‐Balériaux, M., Van Cauter, E., & Copinschi, G. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02341.x · Cited by 167 · cited 2×
“2001), a phase advance of circadian rhythms in healthy human volunteers (Kräuchi et al. 1997 ; Leproult et al. 2005) and depressed patients (Quera-Salva et al.”
BackgroundHolsboer-Trachsler, E., Stohler, R., & Hatzinger, M. (1991) · Psychiatry Research · doi:10.1016/0165-1781(91)90041-m · Cited by 160
Cited by
Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects
Mahar, I., Bambico, F. R., Mechawar, N., & Nobrega, J. N. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.11.009 · Cited by 694
The role of 5-HT receptors in depression
Yohn, C. N., Gergues, M. M., & Samuels, B. A. (2017) · Molecular Brain · doi:10.1186/s13041-017-0306-y · Cited by 485
Guardiola‐Lemaitre, B., De Bodinat, C., Delagrange, P., Millan, M. J., Munoz, C., & Mocaër, E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12720 · Cited by 182
Self-citationSiopi, E., Denizet, M., Gabellec, M.-M., de Chaumont, F., Olivo-Marin, J.-C., Guilloux, J.-P., Lledo, P.-M., & Lazarini, F. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2817-15.2016 · Cited by 111
“FLX restored both proliferation and survival of progenitor cells in the DG, as previously reported (David et al., 2009; Rainer et al., 2012; Guilloux et al., 2013).”
ResultSelf-citationRole of melatonin in mood disorders and the antidepressant effects of agomelatine
Srinivasan, V., De Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.711314 · Cited by 84
Metadata
- Authors
- Rainer, Q., Xia, L., Guilloux, J.-P., Gabriel, C., Mocaër, E., Hen, R., Enhamre, E., Gardier, A. M., & David, D. J.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-08
- Volume
- 15
- Issue
- 03
- Pages
- 321-335
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2166636921
- Cited by
- 122
- References
- 12
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. https://app.cochat.ai/papers/10.1017/s1461145711000356
- The paper
- Rainer, Q., Xia, L., Guilloux, J.-P., Gabriel, C., Mocaër, E., Hen, R., Enhamre, E., Gardier, A. M., & David, D. J. (2012). Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145711000356
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.